OVERVIEWPolyPid is developing D-PLEX500* with its collaborator, MIS Implants Technologies Ltd., a subsidiary of Dentsply Sirona Inc., for use in periodontal and oral/maxillofacial surgeries to treat peri-implantitis, a destructive inflammatory process affecting the soft and hard tissues surrounding dental implants.D-PLEX500 is a member of our PLEX-doxycycline family that incorporates a synthetic bone graft substitute comprised…
Read more >OVERVIEWPolyPid has developed D-PLEX1000*, another product candidate from the PLEX-doxycycline family, for use in connection with orthopedic surgeries for the prevention of SSIs and support of bone recovery. Often, bone will not heal in the presence of infection.D-PLEX1000 is designed for filling bone voids, providing effective eradication of bone infection caused by doxycycline-sensitive microorganism around…
Read more >
PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.
Read More >
Is designed to prevent the risk of surgical site infections in both bone and soft tissue through its cutting-edge, local, extended-release mechanism
Read More >
Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.
Read More >